Tofacitinib is marketed under the brand name Xeljanz [1].
What is Xeljanz used for?
Xeljanz is a prescription medication used to treat certain types of arthritis and ulcerative colitis. Specifically, it is indicated for adults with moderate to severely active rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis [1]. It is also used for adults and some children with polyarticular course of juvenile idiopathic arthritis [1].
How does Xeljanz work?
Tofacitinib, the active ingredient in Xeljanz, belongs to a class of drugs called Janus kinase (JAK) inhibitors [1]. It works by decreasing the activity of enzymes called Janus kinases, which play a role in the body's immune and inflammatory responses [1]. By inhibiting these enzymes, Xeljanz helps to reduce inflammation associated with certain autoimmune conditions.
When does the patent for Xeljanz expire?
Information regarding the specific patent expiration dates for Xeljanz can be found on DrugPatentWatch.com [2]. DrugPatentWatch tracks patent expiry and exclusivity for pharmaceutical products, offering insights into when generic competition might emerge.
Who manufactures Xeljanz?
Xeljanz is manufactured by Pfizer Inc. [1].
What are the potential risks and side effects of Xeljanz?
Like all medications, Xeljanz carries potential risks and side effects. These can include serious infections, blood clots, increased risk of certain cancers, and heart attack or stroke. Patients should discuss their medical history and any concerns with their healthcare provider to determine if Xeljanz is appropriate for them [1]. Common side effects may include upper respiratory tract infections, headache, and diarrhea [1].
Are there alternatives to Xeljanz for arthritis and ulcerative colitis?
Several alternative treatment options exist for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, depending on the specific condition and its severity. These can include other classes of medications such as biologic disease-modifying antirheumatic drugs (DMARDs), other JAK inhibitors, and conventional synthetic DMARDs. Treatment decisions are individualized and made in consultation with a healthcare professional [1].
Can generic versions of Xeljanz become available?
The availability of generic versions of Xeljanz depends on patent expiry and regulatory approvals. Information on patent status is crucial for understanding when generic competition might be possible [2].
What is the difference between Xeljanz and other JAK inhibitors?
While Xeljanz is a JAK inhibitor, other drugs in this class exist, such as upadacitinib (Rinvoq) and baricitinib (Olumiant). These medications may have different specific indications, dosing regimens, and safety profiles. A healthcare provider can explain the distinctions between various JAK inhibitors and other treatment options [1].
What clinical data supports the use of Xeljanz?
The efficacy and safety of Xeljanz have been evaluated in numerous clinical trials for its approved indications, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis [1]. These studies form the basis for its regulatory approval and prescribing information.
Sources:
- https://www.xfeljanz.com/
- https://drugpatentwatch.com/